Pushing 'value,' Harvard Pilgrim tests outcomes deals

BioPharma Dive

18 April 2018 - Harvard Pilgrim will pay less for AstraZeneca plc's asthma drug Symbicort if its members experience worsening symptoms beyond a predetermined level set by an outcomes-based contract the two companies announced on April 18.

Under the agreement, Harvard Pilgrim will monitor asthma-related symptoms for members taking Symbicort and compare their experience to the clinical trial results reported by AstraZeneca for the combination anti-inflammatory medicine.

It's the third outcomes-based deal the New England-based insurer has inked with the pharma, adding to previous agreements covering Brilinta and Bydureon.

Read BioPharma Dive article

Michael Wonder

Posted by:

Michael Wonder